Moderna Co-Founder Kenneth Chien on mRNA's Future in Cancer Treatment

Kenneth Chien, co-founder of Moderna, discusses the transformative potential of mRNA technology beyond COVID-19 vaccines, particularly focusing on Moderna's cancer vaccine development. The interview explores how mRNA-based immunotherapies could revolutionize cancer treatment by training the immune system to recognize and attack tumor cells. Chien, who has since left Moderna, remains optimistic about the company's pipeline and the broader applications of mRNA technology in oncology. This advancement represents a significant shift in biotech innovation toward personalized and targeted cancer therapies.

Originally published on
STAT News
By Jason Mast
Read full article(opens in new tab)Fetched: June 29, 2026 at 10:11 AM



